ADT 030
Alternative Names: ADT-030Latest Information Update: 29 Dec 2025
At a glance
- Originator ADT Pharmaceuticals
- Class Antineoplastics; Indenes; Small molecules
- Mechanism of Action Phosphodiesterase 10A inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Colorectal cancer; Lung cancer; Pancreatic cancer
Most Recent Events
- 29 Dec 2025 ADT 030 is still in preclinical trials for Lung cancer in US
- 22 Oct 2025 Preclinical trials in Pancreatic cancer in USA (PO), before October 2025
- 22 Oct 2025 Pharmacodynamic and adverse events data from a preclinical study in Lung cancer, Pancreatic Cancer, Breast cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025 2025)